ArticleQuantitative imaging in medicine and surgery2024
Preoperatively predicting human epidermal growth factor receptor 2-low expression in breast cancer using neural network model based on multiparameter magnetic resonance imaging.
Article in Quantitative imaging in medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinomaFrontiers in immunology · 2025Article
- Enhancing preoperative HER2 status classification of invasive breast cancers using machine learning models based on clinicopathological and MRI features: a multicenter study.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preoperative prediction of human epidermal growth factor receptor 2 (HER2)-low expression using magnetic resonance imaging (MRI) can enhance the selection of clinical treatment strategies and enhance patient outcomes. Herein, we investigated the value of a neural network model constructed with multiparametric MRI in diagnosing HER2-low breast cancer. Methods: This retrospective study involved two different centers. A total of 895 breast cancer patients (903 lesions) were enrolled from the Second Hospital of Shandong University (known as "Center 1") between January 2015 to December 2022. They were allocated to the training set (626 cases/632 lesions) and the internal validation set (269 cases/271 lesions). The external validation set included 100 patients (100 lesions) from the Qilu Hospital of Shandong University (referred to as "Center 2") between June 2021 to December 2022. All patients were subgrouped into HER2-low and HER2-0 expression groups. We used t-tests, Wilcoxon rank sum tests, and Chi-squared tests or Fisher's exact test to compare the dynamic contrast-enhanced MRI features (morphological/hemodynamic features), and the apparent diffusion coefficient (ADC) values. A neural network model was constructed using the Neuralnet package in R, with the architecture specified as c(5,2) for the hidden layers. Bootstrapping was used for internal validation. The diagnostic performance in the training set was analyzed using receiver operating characteristic (ROC) curves. The clinical effectiveness of the model was validated using a decision curve analysis (DCA). Results: HER2-low breast cancer lesions had irregular morphology, high early enhancement rate, and low ADC value compared to HER2-0 expressed lesions. The differences were significant (P<0.05). We then constructed a neural network model using these significant variables. ROC analysis showed that the area under the ROC curve of the model for diagnosing HER2-low breast cancer in the training, internal validation, and external validation sets was 0.757 [95% confidence interval (CI): 0.712-0.802], 0.728 (95% CI: 0.658-0.798), and 0.791 (95% CI: 0.693-0.890), respectively. The DCA demonstrated that the net benefit of the model was significantly greater than zero at a predicted probability of 0.764. Conclusions: The neural network model based on MRI features is an effective tool in predicting HER2-low breast cancer, which may facilitate clinical treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.